中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 4
Apr.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(4): 918-922

Low-dose defibrotide in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome： A case report

DOI: 10.12449/JCH260421
  • 1.

    Third Department of Liver Disease Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

  • 2.

    Clinical Laboratory Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

Research funding:

Beijing Municipal Administration of Hospitals Incubating Program (PX2023061);

Young Investigator Grant in Beijing YouAn Hospital Affiliated to Capital Medical University (BJYAYY-YN2024-13)

More Information
  • Corresponding author: QIU Lixia， qiulixia@ccmu.edu.cn （ORCID： 0000-0001-9662-8705）
  • Received Date: 2025-11-16
  • Accepted Date: 2025-12-19
  • Published Date: 2026-04-25
    Abstract
  • This article reports a case of a male patient， aged 60 years， who developed pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome （PA-HSOS） due to ingestion of Gynura segetum （Lour.） Merr. The patient presented with ascites and abnormal liver function， and a confirmed diagnosis was made based on radiological examination and liver biopsy. Since the patient was allergic to low-molecular-weight heparin and had no response to supportive therapy， low-dose defibrotide was administered as rescue treatment. After treatment， the patient achieved rapid regression of ascites and recovery of liver function， and liver biopsy reexamination showed alleviation of sinusoidal congestion and hepatocyte regeneration. Self-resolving conjunctival hemorrhage occurred during treatment. This case suggests that for patients with contraindications to standard anticoagulation therapy or those showing no response to such treatment， low-dose defibrotide may be used as an effective and relatively safe alternative treatment regimen.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    WANG CY, WANG YL, ZHAO JB, et al. Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study[J]. Heliyon, 2023, 10( 1): e23455. DOI: 10.1016/j.heliyon.2023.e23455.
    [2]
    NASSEREDDINE S, ALSUBAIT S, TABBARA I. Sinusoidal obstruction syndrome(veno-occlusive disease) following hematopoietic stem cell transplant: Insights and therapeutic advances[J]. Anticancer Res, 2018, 38( 5): 2597- 2605. DOI: 10.21873/anticanres.12501.
    [3]
    DIGNAN FL, WYNN RF, HADZIC N, et al. BCSH/BSBMT guideline: Diagnosis and management of veno-occlusive disease(sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J]. Br J Haematol, 2013, 163( 4): 444- 457. DOI: 10.1111/bjh.12558.
    [4]
    CORBACIOGLU S, CARRERAS E, MOHTY M, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Final results from the international compassionate-use program[J]. Biol Blood Marrow Transplant, 2016, 22( 10): 1874- 1882. DOI: 10.1016/j.bbmt.2016.07.001.
    [5]
    KERNAN NA, GRUPP S, SMITH AR, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome[J]. Br J Haematol, 2018, 181( 6): 816- 827. DOI: 10.1111/bjh.15267.
    [6]
    DANAN G, TESCHKE R. RUCAM in drug and herb induced liver injury: The update[J]. Int J Mol Sci, 2015, 17( 1): 14. DOI: 10.3390/ijms17010014.
    [7]
    SHEN T, LIU YX, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156( 8): 2230- 2241. e 11. DOI: 10.1053/j.gastro.2019.02.002.
    [8]
    NEUMAN MG, COHEN L, OPRIS M, et al. Hepatotoxicity of pyrrolizidine alkaloids[J]. J Pharm Pharm Sci, 2015, 18( 4): 825- 843. DOI: 10.18433/j3bg7j.
    [9]
    ROEDER E. Medicinal plants in Europe containing pyrrolizidine alkaloids[J]. Pharmazie, 1995, 50( 2): 83- 98.
    [10]
    ROEDER E, WIEDENFELD H, EDGAR JA. Pyrrolizidine alkaloids in medicinal plants from North America[J]. Pharmazie, 2015, 70( 6): 357- 367.
    [11]
    ROEDER E. Medicinal plants in China containing pyrrolizidine alkaloids[J]. Pharmazie, 2000, 55( 10): 711- 726.
    [12]
    Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolizidine alkaloids-related sinusoidal obstruction syndrome(2017, Nanjing)[J]. J Clin Hepatol, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.

    中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京)[J]. 临床肝胆病杂志, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
    [13]
    LI RQ, LI L, CAI ZH, et al. Histological evaluation of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: Correlation with Drum Tower Severity Scoring[J]. Dig Liver Dis, 2024, 56( 7): 1220- 1228. DOI: 10.1016/j.dld.2023.12.008.
    [14]
    WANG JY, GAO H. Tusanqi and hepatic sinusoidal obstruction syndrome[J]. J Dig Dis, 2014, 15( 3): 105- 107. DOI: 10.1111/1751-2980.12112.
    [15]
    PENG CY, ZHANG XF, ZHANG F, et al. Clinical efficacy and safety of anticoagulation therapy for pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: A retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol, 2020, 32( 9): 1168- 1178. DOI: 10.1097/MEG.0000000000001630.
    [16]
    YANG XQ, YE J, LI X, et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes[J]. World J Gastroenterol, 2019, 25( 28): 3753- 3763. DOI: 10.3748/wjg.v25.i28.3753.
    [17]
    JIANG MJ, WANG LY, DU XD, et al. Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: Five case reports[J]. J Int Med Res, 2020, 48( 9): 0300060520961916. DOI: 10.1177/0300060520961916.
    [18]
    SONG Y, FAN YH. Clinical features of hepatic veno-occlusive disease induced by Gynura root: Analysis of 102 cases[J]. J Clin Hepatol, 2011, 27( 5): 496- 499. DOI: 10.3969/j.issn.1001-5256.2011.05.014.

    宋宇, 樊艳华. 土三七所致肝小静脉闭塞病102例临床分析[J]. 临床肝胆病杂志, 2011, 27( 5): 496- 499. DOI: 10.3969/j.issn.1001-5256.2011.05.014.
    [19]
    ZHU WL, CHEN SH, CHEN WX, et al. Clinical analysis of 50 cases of hepatic veno-occlusive disease[J]. Chin J Dig, 2012, 32( 9): 620- 624. DOI: 10.3760/cma.j.issn.0254-1432.2012.09.013.

    朱晚林, 陈韶华, 陈卫星, 等. 肝小静脉闭塞病50例临床分析[J]. 中华消化杂志, 2012, 32( 9): 620- 624. DOI: 10.3760/cma.j.issn.0254-1432.2012.09.013.
    [20]
    LI S, LI Y, ZHOU CH, et al. Transjugular intrahepatic portosystemic shunt benefits for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum: A propensity score-matched analysis[J]. Cardiovasc Intervent Radiol, 2023, 46( 7): 931- 942. DOI: 10.1007/s00270-023-03451-9.
    [21]
    RICHARDSON PG, TRIPLETT BM, HO VT, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome[J]. Expert Rev Clin Pharmacol, 2018, 11( 2): 113- 124. DOI: 10.1080/17512433.2018.1421943.
    [22]
    KERNAN NA, RICHARDSON PG, SMITH AR, et al. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program[J]. Pediatr Blood Cancer, 2018, 65( 10): e27269. DOI: 10.1002/pbc.27269.
    [23]
    LIU ZL, LIANG S, WEI XH, et al. Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome[J]. BMC Gastroenterol, 2022, 22( 1): 525. DOI: 10.1186/s12876-022-02523-3.
    [24]
    BAGAL B, CHANDRASEKHARAN A, CHOUGLE A, et al. Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation[J]. Hematol Oncol Stem Cell Ther, 2018, 11( 1): 47- 51. DOI: 10.1016/j.hemonc.2017.02.005.
    [25]
    ZHUGE YZ, LIU YL, XIE WF, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2019, 34( 4): 634- 642. DOI: 10.1111/jgh.14612.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (45) PDF downloads(12) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return